Dréno et al. [19] reported that CD8+ T cells, defined by the co-expression of PD-1 and TIGIT, are associated with the efficacy of anti-PD-1 immunotherapy in metastatic melanoma patients. This evidence concerns the gene CD8A and metastatic melanoma.